Maurizio Zangari, MD

Research Program: Cancer Therapeutics Faculty Rank: Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Internal Medicine

Cancer Research Interest

• Disease Site Focus: Multiple Myeloma, Musculoskeletal
• Research Focus Area: Treatment, Detection, Carcinogenesis, Diagnosis/ Prognosis
• Type of Research: Clinical

Contact Information

• Email Address: MZANGARI@UAMS.EDU
• Profiles Research Networking Software: View Profile

Publications

• Guo W, Strouse C, Mery D, [et al., including Zangari M]. A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation. Cancers. 2024 16(6). PMID: 38539451. PMCID: PMC10969019.
• Mohan M, Monge J, Shah N, [et al., including Zangari M]. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood cancer journal. 2024 14(1):35. PMID: 38443345. PMCID: PMC10914756.
• Mohan M, Szabo A, Patwari A, [et al., including Zangari M]. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone marrow transplantation. 2024. PMID: 38361116.
• Guo W, Zhan Y, Mery D, [et al., including Zangari M]. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems. Blood cancer journal. 2024 14(1):30. PMID: 38355688. PMCID: PMC10866867.
• Sun F, Cheng Y, Wanchai V, [et al., including Zangari M]. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nature communications. 2024 15(1):615. PMID: 38242888. PMCID: PMC10798961.
• Al Hadidi S, Ababneh O, Schinke C, [et al., including Zangari M]. Three Years Maintenance with VRD in Multiple Myeloma: Results of Total Therapy IIIB with a 15-Year Follow Up. Blood advances. 2023. PMID: 38052037. PMCID: PMC10845028.
• Guo W, Zhan A, Mery DE, [et al., including Zangari M]. Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS. Blood advances. 2023 7(21):6676-6684. PMID: 37756524. PMCID: PMC10637884.
• Sun F, Cheng Y, Chen JR, [et al., including Zangari M]. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. The Journal of clinical investigation. 2023. PMID: 37883186. PMCID: PMC10760955.
• Cheng Y, Sun F, Alapat DV, [et al., including Zangari M]. High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. Cell reports. Medicine. 2023 4(10):101214. PMID: 37794587. PMCID: PMC10591052.
• Ling W, Johnson SK, Mehdi SJ, [et al., including Zangari M]. EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression. Cancers. 2023 15(18). PMID: 37760488. PMCID: PMC10526862.
• Hammons L, Szabo A, Janardan A, [et al., including Zangari M]. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2023. PMID: 37646658. PMCID: PMC10905074.
• John L, Poos AM, Brobeil A, [et al., including Zangari M]. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. Nature communications. 2023 14(1):5011. PMID: 37591845. PMCID: PMC10435504.
• Fahmawi S, Schinke C, Thanendrarajan S, [et al., including Zangari M]. Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines. Journal of cancer policy. 2023 37:100433. PMID: 37468042.
• Mehdi SJ, Ghatak K, Ling W, [et al., including Zangari M]. Growth and dormancy control of myeloma cells by mesenchymal stem cells. Leukemia research. 2023 133:107355. PMID: 37499483.
• Sun F, Cheng Y, Ying J, [et al., including Zangari M]. A gene signature can predict risk of MGUS progressing to multiple myeloma. Journal of hematology & oncology. 2023 16(1):70. PMID: 37386588. PMCID: PMC10308756.
• Mohan M, Gong Z, Ashby TC, [et al., including Zangari M]. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Cancer. 2023. PMID: 37282609.
• Abu Za'nouneh FJ, Ababneh O, Schinke C, [et al., including Zangari M]. Variability of definition of high-risk multiple myeloma across phase III clinical trials. EJHaem. 2023 4(2):454-458. PMID: 37206288. PMCID: PMC10188470.
• Mazahreh F, Mazahreh L, Schinke C, [et al., including Zangari M]. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood advances. 2023. PMID: 36857755. PMCID: PMC10331406.
• Al Hadidi S, Dongarwar D, Schinke C, [et al., including Zangari M]. Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma. Clinical hematology international. 2023. PMID: 36737587. PMCID: PMC10241736.
• Al Hadidi S, Szabo A, Esselmann J, [et al., including Zangari M]. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone marrow transplantation. 2022. PMID: 36550200.
• Mohan M, Rein LE, Thalambedu N, [et al., including Zangari M]. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. American journal of hematology. 2022 97(12):E451-E453. PMID: 36097868.
• Al Hadidi S, Dongarwar D, Salihu H, [et al., including Zangari M]. Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States. Clinical hematology international. 2022 4(3):117-120. PMID: 36131130. PMCID: PMC9492819.
• Schinke C, Poos AM, Bauer MA, [et al., including Zangari M]. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood advances. 2022. PMID: 35977111. PMCID: PMC9647426.
• Rasche L, Schinke C, Maura F, [et al., including Zangari M]. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nature communications. 2022 13(1):4517. PMID: 35922426. PMCID: PMC9349320.
• Alqazaqi R, Schinke C, Thanendrarajan S, [et al., including Zangari M]. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA network open. 2022 5(8):e2228877. PMID: 36018590. PMCID: PMC9419017.
• Gai D, Chen JR, Stewart JP, [et al., including Zangari M]. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. The Journal of clinical investigation. 2022. PMID: 35881476. PMCID: PMC9479617.
• Al Hadidi S, Zangari M, van Rhee F. Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions. JAMA oncology. 2022. PMID: 35482363.
• Mohan M, Becnel MR, Shah UA, [et al., including Zangari M]. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. American journal of hematology. 2022. PMID: 35472167. PMCID: PMC10476149.
• Al Hadidi S, Schinke C, Thanendrarajan S, [et al., including Zangari M]. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA network open. 2022 5(4):e228161. PMID: 35442451. PMCID: PMC9021907.
• Abushukair H, Syaj S, Ababneh O, [et al., including Zangari M]. First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis. American journal of hematology. 2022. PMID: 35358350.
• Larsen K, Spencer H, Mohan M, [et al., including Zangari M]. Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. Journal of clinical medicine. 2022 11(6). PMID: 35329966. PMCID: PMC8955129.
• Mohan M, Gundarlapalli S, Szabo A, [et al., including Zangari M]. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. American journal of hematology. 2022. PMID: 35285981.
• Mikulasova A, Kent D, Trevisan-Herraz M, [et al., including Zangari M]. Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome research. 2021. PMID: 34933939. PMCID: PMC9341503.
• Baker D, Bimali M, Carrillo L, [et al., including Zangari M]. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021 106(12):3215-3218. PMID: 34847659. PMCID: PMC8634177.
• Mohan M, Kendrick S, Szabo A, [et al., including Zangari M]. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood advances. 2021. PMID: 34807986. PMCID: PMC8945288.
• Baker D, Bimali M, Carrillo L, [et al., including Zangari M]. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021. PMID: 34382384.
• Yarlagadda L, Boerma M, Gundarlapalli S, [et al., including Zangari M]. Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. Cancers. 2021 13(16). PMID: 34439174. PMCID: PMC8392190.
• Boyle EM, Rosenthal A, Ghamlouch H, [et al., including Zangari M]. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia. 2021. PMID: 34365473.
• Boyle EM, Rosenthal A, Wang Y, [et al., including Zangari M]. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. British journal of haematology. 2021. PMID: 34244996.
• Mohan M, Szabo A, Yarlagadda N, [et al., including Zangari M]. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. American journal of hematology. 2021. PMID: 34050985.
• Schinke CD, Boerma M, Bird JT, [et al., including Zangari M]. PHF19 inhibition as a therapeutic target in multiple myeloma. Current research in translational medicine. 2021 69(3):103290. PMID: 33894670. PMCID: PMC8316274.
• Mohan M, Tackett A, Kumar M, [et al., including Zangari M]. Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience. Bone. 2021 146:115876. PMID: 33556629. PMCID: PMC8627246.
• Boyle EM, Deshpande S, Tytarenko R, [et al., including Zangari M]. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature communications. 2021 12(1):293. PMID: 33436579. PMCID: PMC7804406.
• Danziger SA, McConnell M, Gockley J, [et al., including Zangari M]. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS medicine. 2020 17(11):e1003323. PMID: 33147277. PMCID: PMC7641353.
• Deshpande S, Tytarenko RG, Wang Y, [et al., including Zangari M]. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. European journal of haematology. 2020. PMID: 33107092.
• Wyeth A, Gokden N, Alapat D, [et al., including Zangari M]. Primary Plasma Cell Neoplasm of the Kidney Without Formation of a Mass and Its Renal Manifestations: An Interstitial Variant of Renal Plasmacytoma?. Clinical lymphoma, myeloma & leukemia. 2020 20(9):e551-e555. PMID: 32576503.
• Choudhury SR, Ashby C, Tytarenko R, [et al., including Zangari M]. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. Journal of hematology & oncology. 2020 13(1):108. PMID: 32762714. PMCID: PMC7409490.
• Tian E, Watanabe F, Martin B, Zangari M. Innate Biomineralization. International journal of molecular sciences. 2020 21(14). PMID: 32650435. PMCID: PMC7404118.
• Schinke C, Boyle EM, Ashby C, [et al., including Zangari M]. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood cancer journal. 2020 10(6):70. PMID: 32555163. PMCID: PMC7303180.
• Mohan M, Weinhold N, Schinke C, [et al., including Zangari M]. Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. British journal of haematology. 2020 189(1):67-71. PMID: 31820442.
• Nishimura KK, Barlogie B, van Rhee F, [et al., including Zangari M]. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood advances. 2020 4(2):422-431. PMID: 31990333. PMCID: PMC6988393.
• Boyle EM, Ashby C, Tytarenko R, [et al., including Zangari M]. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. PMID: 31988198.
• Du Z, Weinhold N, Song GC, [et al., including Zangari M]. A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood advances. 2020 4(1):181-190. PMID: 31935283. PMCID: PMC6960456.
• Radhakrishnan SV, Boyer M, Sherwin CM, [et al., including Zangari M]. A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma. Cell transplantation. 2019 28(12):1624-1631. PMID: 31619057. PMCID: PMC6923548.
• Sawyer JR, Tian E, Walker BA, [et al., including Zangari M]. An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood cancer journal. 2019 9(8):62. PMID: 31399558. PMCID: PMC6689064.
• Rasche L, Alapat D, Kumar M, [et al., including Zangari M]. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2019 33(7):1713-1722. PMID: 30573775. PMCID: PMC6586541.